NL-OMON42930已完成不适用
DUPLO study: Comparison of the microbial composition of the upper gastrointestinal tract in lean and obese subjects<br> - DUPLO-study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •* Age: 25-50y; In case of sufficient eligible subjects, the age distribution of the two groups will be aligned, and the age range will be reduced to max. 10 y between highest and lowest age.
- •* Lean: BMI 19-23 kg/m2, waist circumference <80 cm, and fasting glucose <6.1 mmol/L; Obese: BMI 30-35 kg/m2, waist circumference >88 cm, and fasting glucose ><=6.1 and <7.5 mmol/L
- •* Healthy as assessed by the NIZO lifestyle and health questionnaire (*Verklaring leefgewoonten en gezondheid*)
- •* Healthy as assessed by results of the pre-study safety laboratory tests (clinical chemistry: liver/kidney function etc).
- •* Regular and normal Dutch eating habits as assessed by the NIZO lifestyle and health questionnaire (3 main meals per day)
- •* Regular bowel movement (defecation on average once a day, at least 4 times/week)
排除标准
- •* Participation in any clinical trial with oral, intravenous or inhalatory administration of any substances during 90 days before study start
- •* History or presence of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject*s ability to participate in the study:
- •o type 1 or type 2 diabetes
- •o gastrointestinal disease
- •o bariatric surgery
- •o cardiovascular disease, liver or renal failure or disease of kidney or thyroid gland, cancer
- •o infectious disease, history of chronic active inflammatory disorders, food allergy
- •* Use of antibiotics during the one (1) year prior to study start: if this criterion restricts inclusion too much, we will lower this timeframe to six (6) months.
- •* Constipation/infrequent bowel movement (defecation <4 times per week)
- •* Having diarrhea within 3 months prior to the study start
- •* Use of laxatives, fiber supplements (e.g. lactulose), glucose lowering drugs, insulin, anti-obesity drugs, immunosuppressive drugs (e.g. systemic corticosteroids, cyclosporine, azathioprine, antibodies) during the three (3) months prior to study start
- •* Use of temporary or irregular medication for diabetes, dyslipidemia or hypertension
- •* Use of any prescribed or non-prescribed medication (other than paracetamol) including antacids, analgesics, H2 receptor antagonists, proton pump inhibitors, herbal remedies or anti-inflammatory drugs (e.g. NSAIDs) during the three (3) weeks prior to study start.
- •* Use of pro- or prebiotics during the three (3) months prior to study start
- •* Mental status that is incompatible with the proper conduct of the study
- •* Presence of swallowing or passage disorder
- •* Carrying a pacemaker or any other (implanted) medical electronic device
- •* Scheduled for an MRI scan during the study period
- •* Not willing to have an X-ray if the capsule is not recovered from the faeces
- •* Alcohol consumption > 15 units/week and >3/day, and/or not willing to stop during the study
- •* Drug abuse, and not willing/able to stop this during the study
- •* Heavy exercise or sports training > 10 hours/week
- •* Active or recent participation in a weight loss program including weight change (increase or loss) of >3 kg during the last three (3) months
- •* Reported unexplained weight loss or weight gain of > 5 kg in the year prior to pre-study screening
- •* Reported slimming or medically prescribed diet
- •* Reported special diets such as vegetarian, vegan, macrobiotic, low carbohydrate, dairy-free, or diets with intention to use certain limited food groups only (e.g. paleo diet, egg-grape diet)
- •* Pregnant or planning to become pregnant during the study, breastfeeding (subjects will be asked to perform a urine pregnancy test on the study day, before swallowing the caspule)
- •* Postmenopausal women on unstable hormone replacement therapy (periodical hormone treatment such as contraceptives is no exclusion criterion)
- •* Not willing to accept information-transfer concerning participation in the study, or information regarding health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner
研究者
相似试验
终止
不适用
Comparison of the Microbial Composition in Lean and Obese SubjectsObesityNCT03075228NIZO Food Research10
已完成
不适用
Evaluation of microbial pollution related to periodontal paks after periodontal surgery. SurgeryPeriodontal Diseases.Periodontal Diseases UnspecifiedIRCT201011034877N2Vice chancellor for research, Faculty of Dentistry, Isfahan University of Medical Sciences64
已完成
不适用
Microbiological and clinical evaluation of different implant surface decontaminating procedures in the surgical treatment of peri-implantitis; a double blind placebo controlled randomized clinical study.infection of the gingiva surrounding a dental implantperi-implantitis10004018NL-OMON33406niversitair Medisch Centrum Groningen30
已完成
不适用
Comparison of presence of microorganisms and measurement of calcium , phosphorus . magnesium, sodium and potassium fresh samples collected from the patient side, at home and after pasteurizatioutrition child, growth and development, breastfeeding , nutrition, human milkA12.200.467E02.421.360Q50.020F01.145.407.199SP4.011.102.093RBR-7994vzFaculdade de Ciências Médicas da Universidade Estadual de Campinas
招募中
不适用
Comparative in vitro investigation of the bacterial colonisation of a novel hydrogel-covered and protein-rejecting double-J-ureterstent vs. commercially available standard double-J-ureterstentbiofilm layer on ureter splintsDRKS00013264niversitätsklinikum Freiburg